AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18821638 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions for arthritis
Number of subjects: 25
Study 15956038 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFEV (CMF plus epirubicin and vincristine)
Number of subjects: 211
Study 15956038 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 211
Study 11226117 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 36
Study 11226117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 36
Study 11226117 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 36
Study 9776796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary recall method
Number of subjects: 7
Study 9776796 — intervention group
Group type: EXPERIMENTAL
Intervention: Training effect during the study
Number of subjects: 7
Study 7830214 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced child involvement condition
Number of subjects: 0
Study 7830214 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment condition
Number of subjects: 0
Study 2893533 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16
Study 2893533 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 16
Study 2893533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1441970 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial phenolization of the germinal matrix
Number of subjects: 0
Study 21610 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 494
Study 21610 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin hydrochloride
Number of subjects: 494
Study 21610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 31170542 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Challenge (DC)
Number of subjects: 159
Study 31170542 — intervention group
Group type: COMPARATOR
Intervention: Penicillin Skin Testing (PST)
Number of subjects: 159
Study 28203730 — intervention group
Group type: COMPARATOR
Intervention: Neutral head position
Number of subjects: 51
Study 28203730 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended head position
Number of subjects: 51
Study 28203730 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexed head position
Number of subjects: 51
Study 28203730 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotated head position
Number of subjects: 51
Study 25523633 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin (100mg twice daily)
Number of subjects: 180
Study 25523633 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100mg once daily)
Number of subjects: 180
Study 24554938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 96
Study 24554938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24554938 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 19573436 — intervention group
Group type: EXPERIMENTAL
Intervention: High amino acid group (HP): 2.4 g/(kg.d) of amino acid IV within 24 hours after birth
Number of subjects: 96
Study 19573436 — intervention group
Group type: EXPERIMENTAL
Intervention: High amino acid group (HP)
Number of subjects: 96
Study 16708511 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted environmental and educational intervention (dust mite covers, professional house cleaning, roach bait and trays)
Number of subjects: 410
Study 16708511 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (no immediate intervention)
Number of subjects: 410
Study 16708511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 410
Study 16708511 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 410
Study 16159869 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg body weight for 6 days
Number of subjects: 30
Study 16159869 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 30
Study 16159869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11579299 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with ATG
Number of subjects: 309
Study 11579299 — intervention group
Group type: COMPARATOR
Intervention: Immediate tacrolimus-based triple therapy
Number of subjects: 309
Study 9585718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day for 7 weeks)
Number of subjects: 27
Study 9585718 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (3 weeks treatment)
Number of subjects: 27
Study 8142644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu‐M195 at 0.5, 1.0, 3.0, and 10.0 mg/m2
Number of subjects: 13
Study 8142644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu‐M195 at 3 mg/m2
Number of subjects: 13
Study 8142644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu‐M195
Number of subjects: 13
Study 3344597 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg (i.m.)
Number of subjects: 203
Study 3344597 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg (i.m.)
Number of subjects: 203
Study 3344597 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 80 mg (i.m.)
Number of subjects: 203
Study 3344597 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (Butorphanol 4 mg, Butorphanol 2 mg, Meperidine 80 mg)
Number of subjects: 203
Study 28439928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation (UI)
Number of subjects: 50
Study 28439928 — intervention group
Group type: COMPARATOR
Intervention: Needle irrigation (NI)
Number of subjects: 50
Study 28982656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention addressing the obesogenic environment
Number of subjects: 736
Study 28982656 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 736
Study 25396353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 0
Study 23494582 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 160
Study 23494582 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 23494582 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Number of subjects: 160
Study 23494582 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain in situ
Number of subjects: 160
Study 21266302 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Behavioral Management (CBM)
Number of subjects: 431
Study 21266302 — intervention group
Group type: COMPARATOR
Intervention: Standard Parole
Number of subjects: 431
Study 19825186 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical CVP reduction by clamping of the IVC
Number of subjects: 0
Study 19825186 — intervention group
Group type: COMPARATOR
Intervention: Anaesthesiological CVP without infrahepatic IVC clamping reduction
Number of subjects: 0
Study 16955042 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleradiology (TR)
Number of subjects: 710
Study 16955042 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Consultation (VC)
Number of subjects: 710
Study 16955042 — intervention group
Group type: COMPARATOR
Intervention: Telephone Consultation (TC)
Number of subjects: 710
Study 15089081 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11216323 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of irrelevant information with strong relevant S-R association (arrow direction to keypress)
Number of subjects: 0
Study 11216323 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of irrelevant information with weak relevant S-R association (colour word to keypress)
Number of subjects: 0
Study 11216323 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak irrelevant colour word with 500 ms SOA
Number of subjects: 0
Study 11216323 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak irrelevant physical colour with 500 ms SOA
Number of subjects: 0
Study 11216323 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression
Number of subjects: 0
Study 11216323 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended SOAs of 3 s
Number of subjects: 0
Study 9756188 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline withdrawal for 6 weeks
Number of subjects: 38
Study 9756188 — intervention group
Group type: COMPARATOR
Intervention: Continued theophylline treatment (400 mg/day) for 6 weeks
Number of subjects: 38
Study 7870401 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative 67Ga-citrate lung scanning in SLE patients
Number of subjects: 34
Study 7870401 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative 67Ga-citrate lung scanning in SLE patients with flare stage or negative chest X-ray
Number of subjects: 34
Study 7870401 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (20 individuals)
Number of subjects: 34
Study 3407871 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 50 mg
Number of subjects: 52
Study 3407871 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 15 mg
Number of subjects: 52
Study 3407871 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 25 mg
Number of subjects: 52
Study 3407871 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 15 mg, 25 mg, 50 mg
Number of subjects: 52
Study 31317599 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMA)
Number of subjects: 140
Study 31317599 — intervention group
Group type: COMPARATOR
Intervention: Individual appointments (IA)
Number of subjects: 140
Study 31317599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SMA and IA
Number of subjects: 140
Study 28341107 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of morphine 0.1 mg kg–1 with levobupivacaine 0.5% (1 mg kg–1; group LevoBM)
Number of subjects: 26
Study 28341107 — intervention group
Group type: COMPARATOR
Intervention: Epidural injection of morphine 0.1 mg kg–1 with bupivacaine 0.5% (1 mg kg–1; group BM)
Number of subjects: 26
Study 25952661 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (50 IU kg(-1) dose)
Number of subjects: 0
Study 25952661 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (single and multiple dosing)
Number of subjects: 0
Study 25952661 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (age-based analysis)
Number of subjects: 0
Study 25952661 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (ethnicity-based analysis)
Number of subjects: 0
Study 23590463 — intervention group
Group type: COMPARATOR
Intervention: Stylet
Number of subjects: 178
Study 23590463 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps-guided tube exchanger
Number of subjects: 178
Study 21697704 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - bilateral knee extension (10 sets of 15 repetitions with 90% of 15 repetitions maximum)
Number of subjects: 16
Study 21697704 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - stayed at rest
Number of subjects: 16
Study 19473502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials published in Acta Psychiatrica Scandinavica
Number of subjects: 582
Study 17125500 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic technique
Number of subjects: 80
Study 17125500 — intervention group
Group type: COMPARATOR
Intervention: Conventional open technique
Number of subjects: 80
Study 17125500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study 15282655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional use of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor
Number of subjects: 0
Study 15282655 — intervention group
Group type: COMPARATOR
Intervention: Low-dose unfractionated heparin (UFH) plus planned GP IIb/IIIa inhibitor
Number of subjects: 0
Study 15282655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional use of GP IIb/IIIa inhibitor
Number of subjects: 0
Study 15282655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 11142535 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) therapy
Number of subjects: 49
Study 11142535 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Exposure (SE) therapy
Number of subjects: 49
Study 11142535 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) control
Number of subjects: 49
Study 10184722 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) technologies for teaching coping skills
Number of subjects: 0
Study 1490794 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (A)
Number of subjects: 12
Study 1490794 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation (S)
Number of subjects: 12
Study 2579902 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise program (45 minutes, 3-5 times per week)
Number of subjects: 63
Study 2579902 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 63
Study 31171508 — intervention group
Group type: EXPERIMENTAL
Intervention: anthracycline and cytarabine induction chemotherapy
Number of subjects: 1884
Study 28274173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bakri balloon
Number of subjects: 66
Study 28274173 — intervention group
Group type: COMPARATOR
Intervention: Condom-loaded Foley's catheter
Number of subjects: 66
Study 26392328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg alone
Number of subjects: 9
Study 26392328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg with omeprazole
Number of subjects: 9
Study 26392328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg with rabeprazole
Number of subjects: 9
Study 23959566 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Number of subjects: 74
Study 23959566 — intervention group
Group type: COMPARATOR
Intervention: High-AGE diet
Number of subjects: 74
Study 23959566 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose addition
Number of subjects: 74
Study 23959566 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose addition
Number of subjects: 74
Study 21948118 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartseal sealer and a 0.06 taper Smartpoint calibrated to apical tip size 30
Number of subjects: 40
Study 21948118 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartseal sealer and an F3 SmartpointPT
Number of subjects: 40
Study 21948118 — intervention group
Group type: COMPARATOR
Intervention: AH‐26 sealer and a single F3 ProTaper gutta‐percha cone
Number of subjects: 40
Study 21948118 — intervention group
Group type: COMPARATOR
Intervention: AH‐26 sealer and gutta‐percha using the cold lateral condensation technique
Number of subjects: 40
Study 19576090 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT group (n = 63)
Number of subjects: 127
Study 19576090 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 64)
Number of subjects: 127
Study 17469884 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (AD therapy)
Number of subjects: 240
Study 17469884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 240
Study 15669706 — intervention group
Group type: EXPERIMENTAL
Intervention: Three narrow‐diameter roughened‐surface implants placed in edentulous maxillas using a one‐stage surgical procedure.
Number of subjects: 40
Study 12578902 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network Analysis (ANNA)
Number of subjects: 178
Study 12578902 — intervention group
Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 178
Study 12578902 — intervention group
Group type: COMPARATOR
Intervention: Partin Tables
Number of subjects: 178
Study 12578902 — intervention group
Group type: EXPERIMENTAL
Intervention: Best ANNA
Number of subjects: 178
Study 12578902 — intervention group
Group type: COMPARATOR
Intervention: Best Logistic Regression
Number of subjects: 178
Study 9578186 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 10
Study 9578186 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 10
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 500 mg/day fasting
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 500 mg/day with food
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/day fasting
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/day with food
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1000 mg/day fasting
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1000 mg/day with food
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1500 mg/day with food
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg twice/day with food
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension with TMP-SMX
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension with food
Number of subjects: 22
Study 10610011 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1500 mg/day
Number of subjects: 22
Study 1725026 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril daily
Number of subjects: 661
Study 1725026 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of ramipril in combination with 20 mg of furosemide daily
Number of subjects: 661
Study 1725026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during run-in phase)
Number of subjects: 661
Study 6390537 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone for patients with favorable prognostic indicators and negative staging laparotomy
Number of subjects: 0
Study 6390537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of multiple chemotherapy and radiotherapy for patients with positive laparotomy or unfavorable prognostic indicators
Number of subjects: 0
Study 6390537 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging laparotomy for patients with favorable prognostic indicators
Number of subjects: 0
Study 6390537 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging laparotomy for patients with unfavorable prognostic indicators
Number of subjects: 0
Study 31215538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (main group, n=53)
Number of subjects: 103
Study 31215538 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment (control group, n=50)
Number of subjects: 103
Study 29898066 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + 6% Sodium Hypochlorite (NaOCl)
Number of subjects: 80
Study 29898066 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Number of subjects: 80
Study 29898066 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + 2% Chlorhexidine solution (CHXs)
Number of subjects: 80
Study 29898066 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + Saline solution (SS)
Number of subjects: 80
Study 29898066 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + 6% Sodium Hypochlorite (NaOCl)
Number of subjects: 80
Study 29898066 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Number of subjects: 80
Study 29898066 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + 2% Chlorhexidine solution (CHXs)
Number of subjects: 80
Study 29898066 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + Saline solution (SS)
Number of subjects: 80
Study 26446706 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 0
Study 26446706 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 0
Study 26446706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24290979 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment for opioid dependence
Number of subjects: 58
Study 24290979 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates requiring pharmacotherapy for NAS
Number of subjects: 58
Study 24290979 — intervention group
Group type: COMPARATOR
Intervention: Neonates not requiring pharmacotherapy for NAS
Number of subjects: 58
Study 22906278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cable Pin System (CPS)
Number of subjects: 62
Study 22906278 — intervention group
Group type: COMPARATOR
Intervention: Tension Band Wiring (TBW)
Number of subjects: 62
Study 20060257 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome expectation for exercise (OEE)
Number of subjects: 391
Study 20060257 — intervention group
Group type: EXPERIMENTAL
Intervention: Helplessness
Number of subjects: 391
Study 20060257 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy
Number of subjects: 391
Study 18084949 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with radiotherapy
Number of subjects: 0
Study 18084949 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0
Study 18084949 — intervention group
Group type: COMPARATOR
Intervention: Multimodal approach involving radiotherapy
Number of subjects: 0
Study 18084949 — intervention group
Group type: COMPARATOR
Intervention: Epidermal growth factor receptor monoclonal antibodies (EGFR‐MoABs)
Number of subjects: 0
Study 18084949 — intervention group
Group type: COMPARATOR
Intervention: Anti‐angiogenic drugs
Number of subjects: 0
Study 15650802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subtotal thyroidectomy (Group A)
Number of subjects: 340